admin

Pleasanton, CA – August 28, 2017 – CBT Pharmaceuticals (CBT), a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer, today announced the appointments of Robert A. Figlin, MD, FACP and Frank McCormick, PhD, FRS, DSc. to its newly established Scientific Advisory Board (SAB). […]

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017 Data demonstrates anti-tumor activity in gastric, hepatic, lung and pancreatic cancer models A Phase 1 study of bozitinib in patients with select advanced relapsed/recurrent c-MET dysregulated solid tumors to be initiated in 2017  Santa Clara,

CBT Pharmaceuticals (Australia) Pty Ltd Established Santa Clara, CA – March 30, 2017 – CBT Pharmaceuticals, Inc. (CBT), a life sciences company focused on developing innovative oncology therapeutics, announced today that the first patient has been enrolled in the genolimzumab (CBT-501) Phase 1 study, the company’s first clinical trial. The trial is designed to evaluate

Data demonstrates comparable or improved anti-tumor activity over marketed PD-1 antibody in preclinical model of colon cancer A Phase 1 study of genolimzumab (CBT-501) in patients with select advanced relapsed/recurrent solid tumors to be initiated in 1H 2017 Santa Clara, CA – February 23, 2017 – CBT Pharmaceuticals, Inc. (CBT), a life sciences company focused

CBT Pharmaceuticals Closes $9.75 Million Series A Financing Led by OrbiMed for Development of Oncology Pipeline –$14.75 million total capital raised will advance targeted medicine and immune-oncology programs into the clinic –Gavin Choy, PharmD, MBA, appointed Executive Vice-President and Chief Operating Officer Santa Clara, CA, Aug. 29, 2016 — CBT Pharmaceuticals (CBT), a life sciences